Biotech company Arovella Therapeutics (ASX: ALA), focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment, has achieved a major milestone. It has completed process development for its patent-protected manufacturing process required for large-scale Good Manufacturing Practice (GMP) manufacturing of its lead product, ALA-101. ALA-101 is an “off-the-shelf” CAR-iNKT cell
Read More
Clinical state oncology company Prescient Therapeutics (ASX: PTX) has received the US FDA’s Orphan Drug Designation for its PTX-100 drug, used for cancer treatment. Previously, the Company received ODD for peripheral T-cell lymphomas (PTCL) in 2022. Following that, it applied for ODD for cutaneous T-cell lymphomas (CTCL), and it was granted a blanket designation for
Read More
During the second World War, scientists noted that soldiers exposed to nitrogen mustard gas developed interesting hematologic pathology with significantly reduced white blood cell counts. Researchers began to wonder if the toxins could stop the growth of rapidly dividing cancer cells. It wasn’t long before American pharmacologists Alfred Gilman and Louis Goodman experimented with mustard
Read More
Most company announcements include a one paragraph summary of the business conveniently located at the bottom of the page. Chimeric Therapeutics (ASX: CHM) however, has a one page run down of their business, a clear sign that they work with complex scientific principles and diseases. Whilst investors might initially shy away from the wall of
Read More